Rising prevalence of diabetes is projected to propel the global urinary tract infection market

Published: Aug 2021

The global urinary tract infection market is anticipated to grow at a CAGR of 4.8% during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of diabetes and obesity due to the adoption of unhealthy lifestyles and increasing addiction to alcohol and obesity in many countries. For instance, according to International Diabetes Association in 2019, Diabetes affects approximately 463 million people aged 20 to 79, with the number expected to increase to 700 million by 2045. Diabetes cost the US economy at least $760 billion in 2019, accounting for 10% of total adult spending. Further, Adult obesity rates now exceed 35% in 12 states, 30% in 35 states, and 25% in 48 states, according to the most recent Behavioural Risk Factor Surveillance System (BRFSS) data. Mississippi has the highest adult obesity rate (40.8%), while Colorado and Washington, DC have the lowest (23.8%). Between the years 2018 and 2019,

Browse the full report description Global Urinary Tract Infection Market Size, Share & Trends Analysis Report By Test Type (Biochemical Urinary Tract Infection, Microscopic Urinary Tract Infection, Flow Cytometric Urinary Tract Infection) By Indication (Complicated Urinary Tract Infection, Uncomplicated Urinary Tract Infection, Neurogenic Bladder Infections), End-User (Hospitals & Clinics, and Home Healthcare) Forecast Period 2021-2027 at https://www.omrglobal.com/industry-reports/urinary-tract-infection-treatment-market

Rising acquisitions, product approval, collaborations among the major players if the market also propel the growth of the market. For instance, in July 2019, Recarbrioan antibacterial drug product has been approved by the US Food and Drug Administration (FDA) to treat adults with complicated urinary tract infections and complicated intra-abdominal infections. With this approval The FDA is committed to encouraging the production of new antibacterial drugs that are both safe and reliable, giving patients more choices in the battle against severe infections.

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered- 

o By Test Type

o By Indication

o By End-User

  • Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

  • Competitive Landscape- AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Urinary Tract Infection Market Report Segment

BY Test Type

  • Biochemical Urinary Tract Infection
  • Microscopic Urinary Tract Infection
  • Flow Cytometric Urinary Tract Infection

BY Indication

  • Complicated Urinary Tract Infection
  • Uncomplicated Urinary Tract Infection
  • Neurogenic Bladder Infections

By End-User

  • Hospitals and Clinics
  • Home Healthcare

Global Urinary Tract Infection Market Report Segment by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/urinary-tract-infection-treatment-market